CD19 is a B-cell specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified Fc-domain designed to enhance binding of FcγRIIIa. Herein, we demonstrate that XmAb5574 mediates potent antibodydependent cellular cytotoxicity (ADCC), modest direct cytotoxicity and antibody dependent cellular phagocytosis but not complement mediated cytotoxicity against CLL cells. Interestingly, XmAb5574 mediates significantly higher ADCC as compared to both the humanized anti-CD19 non-engineered antibody it is derived from and also Rituximab, a therapeutic antibody widely utilized in the treatment of CLL. The XmAb5574-dependent ADCC is mediated by natural killer (NK) cells through a Granzyme B dependent mechanism. The NK-cell mediated cytolytic and secretory function with XmAb5574 as compared to the non-engineered antibody is associated with enhanced NK cell activation, interferon production, Erk1/2 phosphorylation downstream of Fcγ receptor and no increased NK cell apoptosis. Notably, enhanced NK-cell mediated ADCC with Xm5574 was enhanced further by Lenalidomide. These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with Lenalidomide for the therapy of CLL and related CD19 + B-cell malignancies.
Introduction
Immunotherapy utilizing monoclonal antibodies (MAbs) is an effective and safe method for the treatment of lymphoid malignancies. 1 Rituximab is a chimeric anti-CD20 monoclonal antibody that was approved for marketing in 1997 and is widely used for the therapy of B-cell lymphoma.
Alemtuzumab is another antibody targeting CD52 that is approved for use in relapsed CLL but is associated with significant toxicity due to the ubiquitous expression of the target antigens on The CD19 antigen is one such potential antigen on the surface of both normal and transformed B-cells but has not been explored as a potential therapeutic antibody target. CD19 is a 95kDa glycoprotein member of the immunoglobulin (Ig) superfamily, and is expressed on follicular dendritic cells and all B-cells from their early pre-B cell stage until the time of plasma cell differentiation. 2, 3 CD19 surface expression is tightly regulated during B-cell development with higher levels seen in more mature cells and CD5+(B-1) B-cells. 2, 4 CD19 is expressed on the surface of B-cells as a multi-molecular complex with CD21, CD81, and CD225 5 and is involved in co-signaling with the B-cell receptor. 6 CD19 deficient mice have been shown to have normal B-cell maturation 7 but decreased proliferative capacity and impaired humoral responses. [7] [8] [9] This suggests that the effects of a CD19 targeting agent may result in the depletion of both malignant, immature B-cells from the lymph nodes and the bone marrow and mature B-cells from the circulation.
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From To date, clinical studies examining CD19 therapeutic antibodies have been limited and directed at B-cell lymphoma. 10 Hooijberg and colleagues demonstrated inferior tumor engraftment protection, growth inhibition, NK-cell ADCC, and monocyte ADCC with several anti-CD19 murine antibodies as compared to anti-CD20 murine antibodies. 11 Recent developments in novel antibody engineering technologies have allowed modification of antigen binding and effector domains of therapeutic antibodies that render efficient target killing and innate immune activation functions. 12 XmAb5574™ is an IgG1, humanized monoclonal antibody targeting the CD19 antigen that was developed by Xencor Inc. utilizing innovative antibody engineering technology. 12 XmAb5574 contains a modified Fc-domain with two amino acid substitutions S239D and I332E that enhances its cytotoxic potency by increased affinity for activatory Fcγ receptor IIIa on effector cells and diminished binding to FcγRIIb. 13 Herein, we explore the preclinical activity of the novel engineered antibody XmAb5574 in CLL and demonstrate that unlike earlier antibodies, it has pre-clinical features suggesting it to be an excellent candidate for future clinical development in this disease.
Patients, Materials and Methods

Patient sample processing and cell culture
All patients enrolled in this study had immunophenotypically defined B-cell CLL as outlined by National Cancer Institute-Working Group 1996 criteria. 14 Blood was obtained from patients after written informed consent in accordance with the Declaration of Helsinki under a protocol approved by the institutional review board of The Ohio State University (Columbus, OH).
Enriched B-cell CLL fractions were negatively selected as previously described. 15 Isolated CLL cells were incubated in RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT), 2 mM L-glutamine (Invitrogen, Carlsbad, CA),
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From and penicillin (56U/mL)/streptomycin (56μg/mL; Invitrogen) at 37°C in an atmosphere of 5% CO 2 . Freshly isolated CLL cells were used for all studies. Samples used were more than 90% Bcells as determined by CD19 surface staining and fluorescence-activated cell sorting (FACS) analysis. Human NK-cells (>75-80% CD56+, <1% CD3+) derived from CLL patients or normal donors were isolated directly from fresh whole blood by 30-minute incubation with NK-cell enrichment RS cocktail prior to ficoll hypaque density gradient centrifugation as above.
Reagents and antibodies
The modified XmAb5574 and XmAb5603 wild type anti-CD19 antibodies were provided by was added to the cell suspension 5 minutes after adding the primary antibodies, at a concentration 5 times that of the primary antibodies (i.e. 50μg/mL for 10μg/mL). For all direct cytotoxicity experiments, a group of samples with the same concentration of Trastuzumab treatment was applied as isotype control. In addition, a group of samples with no treatment was collected as media control, and a group treated with fludarabine (10μmol) was also set up as a positive control for apoptosis.
Laser-scanning confocal microscopy
Binding and internalization of CD19 antibodies (5574 and 5603) in B-CLL cells were examined by laser scanning confocal microscopy. B-CLL cells were incubated with anti-CD19-alexa fluor 488 for 1hr or 4 hrs at 37°C. The cells were then washed three times with PBS (pH=7. 
Assessment of apoptosis by flow cytometry
The apoptosis of cells after incubation with antibodies was measured using Annexin-V/PI 
Complement dependent cytotoxicity (CDC) and Antibody-dependent cellular cytotoxicity (ADCC) assays
For CDC assay, CLL cells at 10 6 /mL were suspended in RPMI 1640 media, media with 30% plasma from normal donor blood sample or media with 30% heat-inactivated (56°C, 30 minutes) plasma. Cells were then treated and analyzed as previously described. 15 Similarly, ADCC activity was determined as described previously 15 by standard 4-hour 51 Cr-release assay. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From maximum release, respectively. NK-cell viability after both the Perforin/Granzyme B and Erk1/2 inhibitor treatments was >90% as assessed by Annexin-V/PI staining.
Antibody-dependent cellular phagocytosis (ADCP) assays
Monocytes were isolated from normal donor whole blood using CD14 positive selection and verified to be at least 98% pure using flow cytometry using PE-Cy7-conjugated anti-CD14. 
Statistical Analysis
All statistical analyses were performed by biostatisticians in the Center for Biostatistics at the Ohio State University. Linear mixed models were used for modeling treatment effects, and patient or normal donor random effects. Hypothesis testing used contrasts which directly answered primary questions, e.g. interaction contrasts were used to directly test inhibitory or synergy hypotheses found in the experiments that test mechanism of action, and ADCC, respectively. Random effects associated with these contrasts were included or subsumed in the random effects portion of the models to avoid biased low estimates of the standard errors of the contrasts. Holm's method was applied to adjust for multiplicity and control the overall family wise Type I error rate at was modestly higher as compared to Trastuzumab (7.4% increase, 95%CI 2.0%, 12.7%, p=0.02, N=9) and was not significantly different from Rituximab (0.6% increase, 95%CI -10.5%, 11.7%, p=0.91, N=9). XmAb5574 was not found to mediate cytotoxicity in a dose-dependent manner (cytotoxicity increased only 4.4% with doses ranging from 0.1μg/ml to 25μg/ml of XmAb5574 at 24-hours, p=0.71 for trend) (data not shown). Therefore a dose of 10μg/ml was selected for further experiments based upon studies demonstrating that other antibodies such as Rituximab are saturated at 10μg/ml, and also to provide equivalence of controls for the subsequently described effector cell studies that all utilized CLL cells as targets.
We next investigated whether the modified Fc-domain on XmAb5574 is efficient in mediating complement dependent cytotoxicity (CDC) against primary CD19 + CLL cells. Serum was obtained from healthy volunteers to perform CDC assays which revealed the inability of at E:T ratio of 25:1 was 26.9% (95%CI 14.5%, 39.2%), which was significantly greater than the difference at E:T ratio 0:1 (difference was -3.0%, 95%CI -15.4%, 9.3%). The p-value for this synergistic interaction test was 0.0004. For the comparison with Rituximab at the highest effector to target ratio used (25:1, N=11), XmAb5574 revealed greater ADCC (33.5% higher, 95%CI 20.8%, 46.2%, p<0.0001) ( Figure 2B ).
More physiologically relevant, but technically difficult is evaluation of antibody therapeutics using autologous derived NK-cells in conjunction with CLL tumor cells. We therefore studied XmAb5603 at E:T ratio of 25:1 was 23.6% (95%CI 6.0%, 41.2%), which was significantly greater than the difference at E:T ratio 0:1 (-7.9%, 95%CI -25.5%, 9.7%). The p-value for this synergy interaction test was p=0.004. For the comparison with Rituximab we also found XmAb5574 to show greater ADCC (27.1% higher, 95%CI 9.9%, 44.3%, p=0.002, N=5) at E:T of 25:1 ( Figure 2C ). In addition, we confirmed a trend of increasing cytotoxicity mediated by XmAb5574 with a higher effector to target cell ratio (23.9% and 24.1% increase from E:T =6.25 to 25:1, 95%CI 9.4%, 38.3% and 12.9%, 35.3%, p=0.006 and p<0.0001 for trend, in the autologous and allogeneic settings, respectively). 
XmAb5574 mediated NK-cell ADCC against CLL cells is Mediated Predominantly by
org From inhibitor at the tested concentration did not significantly alter XmAb5574 ADCC cytotoxicity against CLL cells. Interestingly, the suppression of ADCC mediated by XmAb5603 was complete with Granzyme B and Perforin inhibitors unlike that observed with XmAb5574, suggesting the improved ability of XmAb5574 to overcome this inhibition at similar concentrations.
XmAb5574 functionally activates NK-cells CD107a production, IFN-γ secretion, and
Erk1/2 phosphorylation
XmAb5574 mediates improved ADCC through a Granzyme B dependent killing process. We next sought to confirm that this enhanced ADCC by XmAb5574 was a consequence of enhanced NK-cell activation. Release of cytokines and cytolytic Granzyme B that promotes NK-cell cytotoxicity occurs via a process of degranulation, during which NK-cells express Lysosomal Associated Membrane Protein-1 (LAMP-1; CD107a) on their membrane which can be utilized as a surrogate for their cytotoxic potential. 33 We utilized normal donor resting NK-cells and exposed them to fixed XmAb5574, XmAb5603, Rituximab, or Trastuzumab and evaluated the expression of CD107a on the surface of these NK-cells, in order to provide a functional assessment of the ability of XmAb5574 to activate NK-cells. Fixed antibody conditions were utilized to perform these experiments and after a 4-hr incubation period NK-cells exposed to XmAb5574 had a much higher expression of CD107a compared to XmAb5603 (19.4% increase, 95%CI 9.6%, 29.2%, p=0.005, N=5), and when compared to Rituximab, the difference was 12.8% (95%CI 0.2%, 25.3%, p=0.04, N=5) ( Figure 4A) . A representative density plot of enhanced CD107a induction by XmAb5574 in CD56+ NK-cells is shown in Figure 4B .
For transduction mechanisms in NK-cells, we utilized our immobilized antibody conditions described above to stimulate normal donor NK-cells and assessed Erk1/2 phosphorylation by immunoblot using anti-phospho-and non-phospho Erk1/2 antibodies. As shown in Figures 5A and B, compared to the control XmAb5603, XmAb5574 increased Erk1/2 phosphorylation which could be partially reversed by the addition of Erk1/2 inhibitor PD9809. A similar effect was observed in the reduction of ADCC in the presence of Erk1/2 inhibitor ( Figure 5C ).
Collectively, these data provide distinct biochemical evidence of XmAb5574 antibody activation 40 In Figure 5D we demonstrate that despite enhanced activation of NK-cells and enhanced FcγRIIIa binding by XmAb5574, no significant cytotoxicity was observed as compared to the parent antibody or rituximab. This finding diminishes concern that XmAb5574 will be directly cytotoxic toward NK-cells in vivo.
XmAb5574 mediated NK-cell ADCC against CLL cells can be Enhanced Further by Lenalidomide
Recruitment of innate effector elements by therapeutic antibodies can occur through both 
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